Clinical trials: Insulin Pump Therapy
Type 1 Diabetes Mellitus
VV-14299 and VV-14300 for the Treatment of Type 1 Diabetes
This study is testing VV-14299 and VV-14300 or VV-14300 alone in adults with long-standing type 1 diabetes (T1D) whose blood sugar is not well controlled despite using an automated insulin delivery (AID) system.
- Trial name
- PROGRESS (NCT07829302)
- Testing
- VV-14300, VV-14299
- Where
- Australia
- Volunteers
- 29 people
- Sponsor
- Kriya Therapeutics, Inc.
Type 1 Diabetes (T1D)
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) Systems
TTP399-206 is a Phase 2a multicenter double blind cross over randomized study of cadisegliatin in participants with T1D using hybrid closed loop systems to manage their diabetes.
- Trial name
- Hybrid CATT1 (NCT07616206)
- Testing
- Cadisegliatin 800 mg QD
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- vTv Therapeutics
Diabetes Mellitus, Type 1
DBLG1 System With TERUMO MEDISAFE WITH Insulin Pump Trial
This study conducted in 90 adults living with type 1 diabetes is an interventional single-arm open-label before/after multicentric national study conducted as a clinical investigation according to the law EU 2017/745 art. 62.
- Trial name
- BETTER (NCT05628532)
- Testing
- Use of the DBLG1 system
- Where
- 10 sites in France
- Volunteers
- 90 people
- Sponsor
- Diabeloop
Type 2 Diabetes, Type 1 Diabetes
European, Open-label, Prospective, Multinational, Multicenter Study in Adult Subjects With Type 1 or Type 2 Diabetes Previously on MDI or CSII Therapy. Subjects Home Setting is Considered Routine Practice.
Accu-Chek® Insight Insulin Pump EU Study is a Multicenter Study to evaluate the Accu-Chek® Insight Insulin Pump in routine practice.
- Trial name
- NCT02105103
- Testing
- Accu-Chek® Insight Insulin Pump
- Where
- 8 sites in Austria, United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Type 2 Diabetes Mellitus
Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump.
This study aims at describing the glucose level by automated glucose sensors and correlating it with insulin delivery and meals over 14 days in insulin-requiring T2D patients living in real-life conditions.
- Trial name
- CLOSE (NCT03436212)
- Testing
- Continuous Glucose Monitoring (CGM)
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Air Liquide Santé International
Type 2 Diabetes
Pilot Study Assessing Insulin Pump Therapy in Type 2 Diabetes
16-week, open-label, multi-center pilot study. Insulin pump naïve subjects with type 2 diabetes who are not achieving glycemic targets (screening A1C ≥ 7.0%) on an established regimen of either: 1) ≥ 2 OAs (Cohort A), 2) basal…
- Trial name
- NCT00922649
- Testing
- Insulin Pump therapy
- Where
- 6 sites in United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Animas Corporation
Type 1 Diabetes
Omnipod 5 System Compared to Pump Therapy
Subject will undergo a 14-day outpatient, standard therapy phase during which sensor and insulin data will be collected. This will be followed by a 90-day outpatient phase where subjects will either use the Omnipod 5 system or…
- Trial name
- NCT05409131
- Testing
- Omnipod 5 System
- Where
- 14 sites in United States, France
- Volunteers
- 196 people
- Sponsor
- Insulet Corporation
Diabetes Mellitus, Type 2
OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy
The purpose of this study is to evaluate the comparative effectiveness of insulin pump therapy versus multiple daily injections in insulin-taking type 2 Diabetes Mellitus who are sub optimally controlled with multiple daily…
- Trial name
- OpT2mise (NCT01182493)
- Testing
- Insulin Pump (Medtronic Minimed Paradigm® VEO)
- Where
- 36 sites in United States, Austria and 11 more
- Volunteers
- 331 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 2 Diabetes Mellitus
Safety and Efficacy Study of Insulin Lispro Versus Insulin Aspart in Participants With Type 2 Diabetes on Insulin Pump Therapy
This study will provide information on the use of insulin lispro and insulin aspart in insulin pumps in participants with type 2 diabetes.
- Trial name
- NCT01474538
- Testing
- Insulin Lispro, Insulin Aspart
- Where
- 12 sites in United States
- Volunteers
- 122 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 2
A Study of the Treatment of Type 2 Diabetes With an Insulin Infusion Pump
This trial is conducted in the United States of America (USA). This is an in-patient trial investigating stepwise dose increase in a period of up to 3-weeks followed by a 10-week out-patient maintenance period.
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Delivery Systems
- Trial name
- NCT00115973
- Testing
- pump, insulin aspart
- Where
- 6 sites in United States
- Volunteers
- 71 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes, Eating Disorders
Eating Disorders in Type 1 Insulin-dependent Diabetes Patients
The purpose of this study is to determine the prevalence of eating disorders in type 1 insulin-dependent diabetes patients
- Trial name
- Diaboulimia (NCT04506216)
- Testing
- cohort
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Icadom
Type 1 Diabetes Mellitus
To Evaluate the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin During Subcutaneous Insulin Pump Therapy
The purpose of this study is to evaluate the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin during SC Insulin Pump Therapy.
- Trial name
- NCT01110746
- Testing
- Viaject 7, LISPRO
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Biodel
Diabetes Mellitus, Type 1
A Study of LY900027 Given by Insulin Pump to Participants With Type 1 Diabetes Mellitus
The main purpose of this study is to learn more about a new formulation of insulin lispro when given by an insulin pump to participants with type 1 diabetes mellitus.
- Trial name
- NCT04161976
- Testing
- LY900027, Insulin Lispro
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes Mellitus
A Study Comparing LY900014 to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Using Insulin Pump Therapy
The reason for this study is to compare the study drug LY900014 to insulin lispro (Humalog) when both are used in insulin pump therapy in adults with type 1 diabetes (T1D).
- Trial name
- PRONTO-Pump-2 (NCT03830281)
- Testing
- Ultra-Rapid Lispro, Insulin Lispro
- Where
- 83 sites in United States, Australia and 9 more
- Volunteers
- 471 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
A Study of LY900014 Formulation in Participants With Type 1 Diabetes Mellitus Using Insulin Pumps
This study evaluated a blood sugar lowering insulin, LY900014, delivered by an insulin pump continuously under the skin. The study was conducted in participants with type 1 diabetes mellitus to investigate how the human body…
- Trial name
- NCT02703324
- Testing
- LY900014, Insulin Lispro
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes
Study to Compare Efficacy of the MiniMed Paradigm REAL-Time System Vs. MDI in Subjects Naive to Insulin Pump Therapy
Primary Outcomes: Average decrease in A1c from baseline to end of Study Phase (52 weeks) for subjects in the "722 Group" is greater than that for subjects in the "Control (MDI) Group".
- Trial name
- STAR3 (NCT00417989)
- Testing
- MiniMed Paradigm REAL-Time System
- Where
- 30 sites in United States, Canada
- Volunteers
- 485 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Type 1
SWITCH - Sensing With Insulin Pump Therapy to Control HbA1c
The primary objective of this study is to evaluate whether the patients with Type 1 diabetes mellitus in sub-optimal glycemic control can achieve better glycemic control by using the Medtronic MiniMed Paradigm® REAL-Time Pump…
- Trial name
- SWITCH (NCT00598663)
- Testing
- insulin pump with continuous glucose sensing (Paradigm Real-Time Insulin Pump System), insulin pump and blinded continuous glucose sensing (Paradigm Real-Time insulin pump)
- Where
- 8 sites in Austria, Denmark and 5 more
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes
Monitoring the Infusion Pressure in Insulin Infusion Sets in Healthy Adults
The purpose of this study is to compare the in-line fluid pressure (pressure of the fluid going through the tubing) and leakage (observation of fluid on and around the device) during and after subcutaneous infusion using two…
- Trial name
- NCT02382536
- Testing
- BD Scarlett Infusion set, Medtronic QuickSet Infusion Set
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Becton, Dickinson and Company
Type1diabetes
Assessment of Two Insulin Pump Insulin Delivery Systems in Type 1 Diabetes.
This is a study of the Minimed 670G 4.0 insulin pump, assessing the efficacy of the Advanced Hybrid Closed Loop (AHCL) algorithm in controlling blood glucose levels in Type 1 Diabetes.
- Trial name
- NCT04073576
- Testing
- AHCL, SAP+PLGM
- Where
- New Zealand
- Volunteers
- 60 people
- Sponsor
- Christchurch Clinical Studies Trust Ltd
Type 2 Diabetes Treated With Insulin
Lifestyle Intervention in Type 2 Diabetes
The purpose of the study is to determine whether a personalized lifestyle intervention focused on diet and physical activity reinforcement is effective in avoiding weight gain in the first months following initiation of…
- Trial name
- WeightPump (NCT02791295)
- Testing
- Diet and physical activity program
- Where
- 6 sites in France
- Volunteers
- 54 people
- Sponsor
- Icadom